On Monday, Revelation Biosciences Inc ( REVB ) announced safety and biomarker data for its Phase 1 study (RVL-HV02).

The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified.

Additionally, statistically significant dose-dependent upregulation of key biomarkers demonstrating the immunostimulatory preconditioning effect of Gemini was observed.

The study enrolled 40 healthy individuals 18 to 55 years of age.

Administration of Gemini induced significant, dose-dependent changes in key circulatory biomarkers of activity that reflect the expected pharmacology of Gemini-specific toll-like receptor 4 (TLR4) stimulation.

Intravenous Gemini induced significant increases in interleukin-1RA (IL-1RA) (p